Skip to main content
. 2013 Mar 21;93(1):1–14. doi: 10.1007/s00223-013-9724-8

Fig. 4.

Fig. 4

Maximum yearly cost (in euros) for an adherence-enhancing intervention to be considered cost-effective [data from 36, 37, 64]. For Sweden, improvement in medication adherence at 25 % should be read at 30 %. In Ireland, a longer refill gap period (9 weeks) was selected to define persistence resulting in higher base-case adherence levels